BMO Capital Maintains Market Perform on Novartis, Raises Price Target to $120
Portfolio Pulse from Benzinga Newsdesk
BMO Capital has maintained its Market Perform rating on Novartis and raised the price target from $118 to $120.
October 30, 2024 | 2:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital has maintained its Market Perform rating on Novartis and increased the price target from $118 to $120, indicating a slightly positive outlook.
The increase in the price target from $118 to $120 by BMO Capital suggests a slightly positive outlook for Novartis, which could lead to a minor positive impact on the stock price in the short term. However, the Market Perform rating indicates that the stock is expected to perform in line with the market.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100